Cruess, D. G., Penedo, F. J., Benedict, C., Lattie, E. G., Molton, I., Kinsinger, D., . . . Soloway, M. (2012). Millon Behavioral Medicine Diagnostic (MBMD) predicts health-related quality of life (HrQoL) over time among men treated for localized prostate cancer. J Pers Assess.

Cruess, Dean G., Frank J. Penedo, Catherine Benedict, Emily G. Lattie, Ivan Molton, Dave Kinsinger, Bruce Kava, Murugesan Manoharan, and Mark Soloway. "Millon Behavioral Medicine Diagnostic (MBMD) Predicts Health-related Quality of Life (HrQoL) Over Time Among Men Treated for Localized Prostate Cancer." J Pers Assess 2012.

Cruess, Dean G., et al. "Millon Behavioral Medicine Diagnostic (MBMD) Predicts Health-related Quality of Life (HrQoL) Over Time Among Men Treated for Localized Prostate Cancer." J Pers Assess 2012.